AU2005314271B2 - Alpha thymosin peptides as cancer vaccine adjuvants - Google Patents

Alpha thymosin peptides as cancer vaccine adjuvants Download PDF

Info

Publication number
AU2005314271B2
AU2005314271B2 AU2005314271A AU2005314271A AU2005314271B2 AU 2005314271 B2 AU2005314271 B2 AU 2005314271B2 AU 2005314271 A AU2005314271 A AU 2005314271A AU 2005314271 A AU2005314271 A AU 2005314271A AU 2005314271 B2 AU2005314271 B2 AU 2005314271B2
Authority
AU
Australia
Prior art keywords
cancer
vaccine
subject
cells
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005314271A
Other languages
English (en)
Other versions
AU2005314271A1 (en
Inventor
Gustavo Antonio Moviglia
Alfred R. Rudolph
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of AU2005314271A1 publication Critical patent/AU2005314271A1/en
Application granted granted Critical
Publication of AU2005314271B2 publication Critical patent/AU2005314271B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2005314271A 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants Ceased AU2005314271B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63317504P 2004-12-06 2004-12-06
US60/633,175 2004-12-06
PCT/US2005/043985 WO2006062917A2 (en) 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants

Publications (2)

Publication Number Publication Date
AU2005314271A1 AU2005314271A1 (en) 2006-06-15
AU2005314271B2 true AU2005314271B2 (en) 2011-06-16

Family

ID=36578462

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005314271A Ceased AU2005314271B2 (en) 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants

Country Status (15)

Country Link
US (1) US20100092499A1 (enExample)
EP (1) EP1835931A4 (enExample)
JP (1) JP2008523067A (enExample)
KR (1) KR20070086663A (enExample)
CN (1) CN101072582B (enExample)
AU (1) AU2005314271B2 (enExample)
BR (1) BRPI0518571A2 (enExample)
CA (1) CA2588685A1 (enExample)
EA (1) EA015510B1 (enExample)
IL (1) IL183264A (enExample)
MX (1) MX2007006717A (enExample)
NO (1) NO20072705L (enExample)
NZ (1) NZ555571A (enExample)
UA (1) UA90493C2 (enExample)
WO (1) WO2006062917A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008338594A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA)
ES2537785T3 (es) * 2009-05-08 2015-06-12 Sciclone Pharmaceuticals, Inc. Péptidos de alfa timosina como potenciadores de vacunas
CN103458681A (zh) * 2011-02-09 2013-12-18 赛生制药有限公司 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽
EP2804626B1 (en) 2012-01-20 2019-05-01 Fernando Thome Kreutz Autologous cancer cell vaccine
WO2013134666A1 (en) * 2012-03-08 2013-09-12 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for treatment of purulent rhinosinusitis
EP3943101A1 (en) * 2014-10-21 2022-01-26 SciClone Pharmaceuticals International Ltd. Treatment of cancer with immune stimulator alpha thymosin peptide
CN107281476B (zh) * 2017-04-06 2020-11-24 中国医科大学 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用
RU2645957C1 (ru) * 2017-04-10 2018-02-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения лучевых повреждений мочевого пузыря
RU2663468C1 (ru) * 2017-09-25 2018-08-06 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653758A (en) * 1900-03-20 1900-07-17 Austin Gale Hay-stacking device.
DE2604845A1 (de) 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
JPH0420624A (ja) * 1990-02-06 1992-01-24 Kanji Yokoe 勾配側溝施工法及び当該工法に使用する可変側溝
NZ516381A (en) * 1999-06-30 2004-03-26 Corixa Corp Lung tumor proteins in the therapy and diagnosis of lung cancer
MXPA04003867A (es) * 2001-10-26 2005-06-17 Rhode Island Hospital Uso de la timosina para aumentar la inmunizacion genetica y composiciones farmaceuticas inmunologicas a base de timosina.
JP2005510491A (ja) * 2001-10-26 2005-04-21 イミュノ−アールエックス， インコーポレイテッド 免疫抑制を逆転させるための免疫治療
US20060052297A1 (en) 2002-06-28 2006-03-09 Guido Rasi Method of up-regulating tumor antigen expression using thymalfasin
DK1613340T3 (da) * 2003-03-28 2010-08-30 Sciclone Pharmaceuticals Inc Behandling af aspergillus-infektioner med thymosin alfa 1
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
ES2537785T3 (es) * 2009-05-08 2015-06-12 Sciclone Pharmaceuticals, Inc. Péptidos de alfa timosina como potenciadores de vacunas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors

Also Published As

Publication number Publication date
AU2005314271A1 (en) 2006-06-15
EP1835931A4 (en) 2008-12-17
NZ555571A (en) 2009-02-28
EA200701166A1 (ru) 2008-02-28
CN101072582B (zh) 2012-06-27
US20100092499A1 (en) 2010-04-15
NO20072705L (no) 2007-09-05
MX2007006717A (es) 2007-08-06
EP1835931A2 (en) 2007-09-26
KR20070086663A (ko) 2007-08-27
CN101072582A (zh) 2007-11-14
CA2588685A1 (en) 2006-06-15
WO2006062917A2 (en) 2006-06-15
IL183264A0 (en) 2007-09-20
EA015510B1 (ru) 2011-08-30
UA90493C2 (ru) 2010-05-11
BRPI0518571A2 (pt) 2008-11-25
IL183264A (en) 2010-12-30
JP2008523067A (ja) 2008-07-03
WO2006062917A3 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
Shimizu et al. Enhancement of tumor lysate-and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein
AU758622B2 (en) Method for activating natural killer (NK) cells
TWI423814B (zh) 用於引發特異性細胞毒性ｔ淋巴細胞（ｃｔｌ）反應之組成物，包含一淋巴去除性化合物以及一含有抗原序列且以專業化抗原呈現細胞為標靶之分子
US20100303868A1 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
CN107488235B (zh) 一种新的增强型抗原联合多肽诱导肝癌特异性ctl细胞的制备及应用
AU2005314271B2 (en) Alpha thymosin peptides as cancer vaccine adjuvants
CN108245673A (zh) 表达Th1特性和溶细胞性质的细胞
Hance et al. The antitumor and immunoadjuvant effects of IFN-α in combination with recombinant poxvirus vaccines
ZA200703528B (en) Immunotherapeutic formulations with Interleukin-2-neutralising capacity
EP1261693A2 (en) Hyperthermia and immunotherapy for leukemias, lymphomas, and solid tumors
RU2192274C2 (ru) Иммуногенная композиция на основе tlp
US20090060946A1 (en) Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
US20200297829A1 (en) Integrative Immunotherapy for Cancer Treatment
WO2004096244A1 (en) Method of preparing tumor vaccine for the inducement of anti-tumor activity and a pharmaceutical composition containing the same
EP4519418A1 (en) Methods for improving t cell efficacy
Smith et al. Immunotherapy in cancer treatment
Schirrmacher et al. Biotherapy of Cancer: Perspectives of immunotherapy and gene therapy
McKechnie et al. Vaccination and malignant disease: Promising therapeutic approach
Salem et al. Tumours: Immunotherapy
Fend et al. Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-a Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
JP2002537265A (ja) 抗腫瘍Ｔｈ１細胞の製造方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired